The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly improved survival benefits. However, the clinical benefits of targeting ALK using TKIs are limited due to the emergence of dr...

Full description

Bibliographic Details
Main Authors: Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao, Fang Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
anaplastic lymphoma kinase (ALK)
TKI - tyrosine kinase inhibitor
resistance
NSCLC
therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.713530/full

Similar Items

Similar Items